Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) have received an average rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is C$22.50.

VRX has been the subject of several research analyst reports. Royal Bank Of Canada lowered their price objective on shares of Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. TD Securities raised shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target for the company in a research report on Wednesday, November 8th.

Shares of Valeant Pharmaceuticals International (VRX) opened at C$20.96 on Friday. Valeant Pharmaceuticals International has a one year low of C$11.20 and a one year high of C$23.75.

In other Valeant Pharmaceuticals International news, Director Schutter Richard Urbain De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Friday, November 17th. The stock was acquired at an average price of C$14.33 per share, with a total value of C$143,300.00.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/24/valeant-pharmaceuticals-international-inc-vrx-given-consensus-recommendation-of-hold-by-brokerages.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (TSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.